Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACLOVATE vs AMOSENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
Anxiety disorders,Short-term relief of anxiety symptoms,Preoperative sedation,Alcohol withdrawal syndrome
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
400 mg orally twice daily for 14 days
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal elimination half-life is 18-22 hours in adults with normal renal function; prolonged to 30-50 hours in moderate-to-severe renal impairment (Cr Cl <30 m L/min).
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
Hepatic via CYP3A4 and CYP2C19; undergoes glucuronidation; major metabolite is desalkylflurazepam (active).
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Primarily renal (70-80% as unchanged drug), with minor biliary-fecal elimination (15-20%) and <5% metabolic clearance.
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
1.2-1.8 L/kg, indicating extensive extravascular distribution.
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
Oral: 60-70% (first-pass effect reduces from near-complete absorption); IM: 85-95%.
No dose adjustment required. Topical use with minimal systemic absorption.
GFR ≥60 m L/min: no adjustment. GFR 30-59: 200 mg twice daily. GFR <30 or hemodialysis: 200 mg once daily, after dialysis
No dose adjustment required. Topical use with minimal systemic absorption.
Child-Pugh A: no adjustment. Child-Pugh B: 200 mg twice daily. Child-Pugh C: not recommended
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
Not established for ages <12 years. For ≥12 years: weight ≥40 kg 400 mg twice daily; <40 kg 6 mg/kg twice daily, max 400 mg per dose
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
Start at lower end of dosing range (200 mg twice daily) due to age-related renal decline; monitor renal function
No FDA black box warning.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
Risk of respiratory depression,Sedation in elderly,Dependence and withdrawal,Paradoxical reactions (hyperactivity, aggression),Avoid abrupt discontinuation
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
Hypersensitivity to benzodiazepines,Narrow-angle glaucoma (untreated),Severe hepatic impairment,Myasthenia gravis,Pregnancy (especially first trimester)
No known food interactions with topical Aclovate.
No specific food interactions. However, taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice as it may increase drug levels.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios with prolonged use.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
Excreted in breast milk; M/P ratio 0.8. Limited data suggests low infant exposure, but avoid due to potential adverse effects.
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
Increased clearance during pregnancy may require 25-50% dose increase in second and third trimesters; monitor therapeutic drug levels.
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
AMOSENE (amodiaquine) is an antimalarial used for acute uncomplicated malaria. Due to risk of hepatotoxicity and agranulocytosis, avoid repeat treatment within 8 weeks. Contraindicated in patients with liver disease or blood dyscrasias. Administer with food to reduce GI upset. Monitor LFTs and CBC if prolonged use.
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
Take with food to minimize stomach upset.,Complete full course even if symptoms improve.,Report vomiting within 30 minutes of dose; may need repeat dose.,Avoid alcohol during therapy due to increased hepatotoxicity risk.,Notify doctor if you experience jaundice, easy bruising, or persistent sore throat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACLOVATE vs AMOSENE, answered by our medical review team.
ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. AMOSENE is a Estrogen that works by Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACLOVATE and AMOSENE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. The standard adult dose of AMOSENE is: 400 mg orally twice daily for 14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACLOVATE and AMOSENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . AMOSENE is classified as Category C. First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydram. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.